Navigation Links
Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:5/19/2011

SAN DIEGO, May 19, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data from a completed, multi-center, Phase 1, monotherapy, dose-escalation study of BAY 86-9766 in advanced cancer patients will be presented in an Oral Abstract Session at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on Sunday, June 5, 2011.

Presentation details are as follows:Presentation Title:

Safety, Pharmacokinetics, and Pharmacodynamics Results From a Phase 1 Trial of BAY 86-9766 (RDEA119), a MEK Inhibitor, In Patients with Advanced Cancer Session Type/Title:

Oral Abstract Session: Developmental Therapeutics – Experimental Therapeutics Author/Presenter:

Colin Weekes, MD, PhD – Assistant Professor, Division of Medical Oncology, University of Colorado School of MedicineAbstract ID:

3007Date/Time:

Sunday, June 5, 2011 from 9:30 AM – 12:30 PM CDTAbout BAY 86-9766BAY 86-9766 (RDEA119) is a potent and highly selective inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer Healthcare (Bayer). Preclinical and clinical data suggest that BAY 86-9766 has favorable properties, including once-daily oral dosing and excellent selectivity. In addition, BAY 86-9766 has been shown to suppress tumor cell growth in vitro and in vivo. Preclinical in vitro and in vivo oncology studies of BAY 86-9766 have demonstrated significant potential synergy across multiple tumor types when used in combination with other anti-cancer agents, including sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals, Inc.).

About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesin
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
2. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
3. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Ardea Biosciences to Present at Two Upcoming Investor Conferences
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
10. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's ... became available for purchase in Australia and New Zealand, and ... 28 works is, if you think about the definition of ... cellular renewal within your body. If you think about the ... cellular renewal. What RENU 28 does is it works with ...
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2Seeing a molecule breathe 2
... VEENENDAAL, The Netherlands, June 2 ... today announced the creation,of an exclusive partnership and ... for an undisclosed sum. The two companies, headquartered ... the combination,will strengthen Nucletron,s position as global leader ...
... The American Institute of Aeronautics and Astronautics ... top emerging aerospace technologies. Developed by AIAA,s ... following: 1. "Greener Aviation" Technologies including emission ... the Federal Aviation Administration,s Continuous Low Emissions, Energy ...
... First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL , ... to treat Analysis results per FDA agreed upon Statistical Analysis Plan , ... Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021 ... Rate 37.1% vs. 14.3%; p=0.003 , ...
Cached Biology Technology:Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 2Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 3AIAA names top ten emerging aerospace technologies of 2009 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 3Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 4Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 5
(Date:8/21/2014)... use a previously unknown process for harvesting energy and ... a Penn State University scientist has discovered. The discovery ... plant growth, harvesting energy from the Sun, and understanding ... and other lakes worldwide. A paper describing the discovery ... edition of the journal Science on 21 ...
(Date:8/21/2014)... intake, health and quality of life of older adults ... the University of Waterloo receiving close to $1.5 million ... (CIHR). , Professor Heather Keller, of the Faculty ... research chair in nutrition and aging, will receive $979,000 ... in long-term care homes are poorly nourished. The project ...
(Date:8/21/2014)... consists of radiations in the 3.3 to 4.4 nanometre ... biological tissues. New theoretical findings show that it is ... These could be the basis of an optimal technique ... or to be used in high-precision spectroscopy. Now, a ... efficiently generate the harmonic radiationswhich are multiples of an ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Grants will fund landmark aging research at Waterloo 2Water window imaging opportunity 2
... A drug made from the saliva of the Gila ... food. Researchers at the Sahlgrenska Academy, University of Gothenburg, ... ceased their cravings for both food and chocolate. ... diabetes are offered a pharmaceutical preparation called Exenatide, which ...
... 15, 2012) The Mass. Eye and Ear Curing Kids ... help the brain locate sound, identify genes that cause congenital ... for childhood eye cancer. The 2011/2012 Curing Kids Fund grants ... Sense-sation! gala. This year,s grant recipients are: , ...
... are used in gardens, burned for heat and energy, and ... grass family that includes corn, sorghum and sugarcane. Two new, ... (an ornamental that likely is a parent of Miscanthus ... sequencing the M. sinensis genome. The studies reveal ...
Cached Biology News:Drugs from lizard saliva reduces the cravings for food 2Mass. Eye and Ear announces Curing Kids Fund grant recipients 2Maps of Miscanthus genome offer insight into grass evolution 2Maps of Miscanthus genome offer insight into grass evolution 3
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: